Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
This study is a long-term registry designed to keep an eye on the safety and how well Increlex® works for children and teenagers with a condition called Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD). Essentially, it's a way for doctors and researchers to gather information over time about patients who are already taking Increlex® as part of their regular treatment. The goal is to understand the medication's effects, especially its safety, for at least five years after treatment ends. This is not a clinical trial where new treatments are tested, but rather an observational study that collects real-world data from patients in several countries, including the UK, to ensure the medication is used safely and effectively as approved.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is called the Increlex® Global Registry. It's not a typical clinical trial where new medicines are tested. Instead, it's a way for healthcare professionals to keep a close watch on the long-term safety and how well a medicine called Increlex® works in children and teenagers. This particular medicine is used to treat a specific growth condition known as Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD). Essentially, this condition means the body doesn't produce enough of a certain hormone needed for growth.
The main reasons for this registry are to gather important information about any potential side effects of Increlex® over time, and to also understand how effective it is in helping children and teenagers with SPIGFD grow and develop. Data will be collected for at least five years after a patient finishes their treatment, giving a comprehensive picture of its long-term impact. This information is crucial for ensuring the medication continues to be used safely and effectively, benefiting those who need it.
Patients who are already taking Increlex® can be included in this registry. The information gathered helps the medical community understand the real-world experience of using this medication outside of a controlled trial setting. This is important for guiding doctors on how to best prescribe and monitor patients receiving Increlex® for SPIGFD, ultimately leading to better care.
النقاط الرئيسية
- This is a long-term study monitoring an existing medicine, not a new drug trial.
- It collects real-world information on Increlex® for children and teenagers with SPIGFD.
- The main goals are to track long-term safety and effectiveness.
- Participation involves sharing medical information from your routine care.
- You won't be asked to change your treatment or have extra appointments.
- Your data helps improve understanding and care for others with SPIGFD.
من قد يكون مؤهلاً؟
This study is open to children and teenagers aged between 2 and 18 years old.
You might be able to take part if you are currently taking Increlex®, or are about to start taking it, for a condition called Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD). This applies if your doctor has prescribed Increlex® according to the approved guidelines for the medicine in your country, such as the UK.
However, you cannot join if you are already involved in another clinical study looking into Increlex® or any other treatment for growth problems. Also, you can't participate if you have a medical condition that means Increlex® isn't suitable for you, or if you're allergic to any of its ingredients. This includes if you have or are suspected of having cancer, or if your growth plates (the parts of your bones where growth happens) have already closed.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- Are you between 2 and 18 years old?
- Are you currently taking, or planning to start, Increlex® for SPIGFD?
- Are you not currently in another medical study for growth problems or Increlex®?
- Do you not have any medical conditions or allergies that would prevent you from safely taking Increlex®?
- Are your parents or legal guardians willing to give permission for you to participate?
ماذا يتضمن المشاركة؟
If you decide to participate in this registry, it means that information about your Increlex® treatment will be collected and recorded. This is an "observational" study, which means you won't be given any new treatments or asked to do anything differently than your usual medical care. The study aims to gather data from your routine doctor visits and treatment with Increlex®, as prescribed by your doctor.
There are no specific extra visits or special assessments required just for this registry. The duration of your participation will depend on how long you are on Increlex® treatment and will continue for at least five years after your treatment ends to monitor long-term effects. The information will be collected from your existing medical records and follow-up appointments.
المخاطر والفوائد المحتملة
المواقع (58)
- مستشفى الأطفال في مقاطعة أورانجالرمز البريدي المؤكدأورانج، الولايات المتحدة· التوظيف
- University of Miami Leonard M Millerالرمز البريدي المؤكدميامي، الولايات المتحدة· التوظيف
- University Of Miami Leonard M. Millerالرمز البريدي المؤكدميامي، الولايات المتحدة· التوظيف
- D&H National Research Centersالرمز البريدي المؤكدميامي، الولايات المتحدة· منسحب
- مركز سينسيناتي الطبي للأطفالالرمز البريدي المؤكدسينسيناتي، الولايات المتحدة· التوظيف
- UT Southwestern Medical Centerالرمز البريدي المؤكددالاس، الولايات المتحدة· لم يبدأ التوظيف بعد
- Children's Health Specialty Center West Planoالرمز البريدي المؤكدبلانو، الولايات المتحدة· منسحب
- Salzkammergut-Klinik Vöcklabruckالرمز البريدي المؤكدVöcklabruck, Austria· التوظيف
- Hôpital Amiens-Picardieالرمز البريدي المؤكدأميان، فرنسا· تم إنهاؤه
- Centre Hospitalier de Bloisالرمز البريدي المؤكدبلوا، فرنسا· التوظيف
- Hôpital Jean Verdierالرمز البريدي المؤكدبوندي، فرنسا· التوظيف
- Hôpital Femme Mère-Enfantالرمز البريدي المؤكدBron, France· التوظيف
أسئلة شائعة
What is SPIGFD?
SPIGFD stands for Severe Primary Insulin-like Growth Factor-1 Deficiency. It's a condition where the body doesn't produce enough of a specific hormone needed for normal growth.
Is this study testing a new medicine?
No, this study is not testing a new medicine. It's a registry that collects information about Increlex®, a medicine that is already approved and used by patients.
What information will be collected about me?
The registry will collect information about your health, your treatment with Increlex®, and how you respond to it over time. This helps doctors understand its safety and effectiveness.
هل يجب علي القيام بأي شيء إضافي إذا انضممت؟
No, you don't have to do anything extra. The registry will collect information from your usual doctor's appointments and treatments, as prescribed by your medical team.
Can I stop participating in the registry at any time?
Yes, you can choose to stop participating in the registry at any time, for any reason, and it will not affect your medical care or treatment.
كيفية معرفة المزيد
Esteve Global Clinical Development
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.